Home > Products > Hypnofast
Share Print This Page

Hypnofast (Midazolam)
Therapeutic Group: Anesthetic / Critical Care » Sedative Hypnotic
Presentation

Hypnofast 15 mg/3 ml Injection: Each 3 ml ampoule contains Midazolam BP 15 mg (as Midazolam Hydrochloride).

Hypnofast 5 mg/1 ml Injection: Each 1 ml ampoule contains Midazolam BP 5 mg (as Midazolam Hydrochloride).

Hypnofast 5 mg/5 ml Injection: Each 5 ml ampoule contains Midazolam BP 5 mg (as Midazolam Hydrochloride).

Descriptions
Midazolam is a sleep inducing agent characterized by a rapid onset and short duration of action. It also exerts an anxiolytic, anticonvulsant and muscle-relaxant effect.
Indications
Short-term treatment of insomnia.

Sedation in premedication before surgical or diagnostic procedures.
Dosage & Administration
Oral dosage: For adults 7.5-15 mg daily. In elderly and debilitated patients, the recommended dose is 7.5 mg. In premedication, 15 mg of Midazolam should be given 30-60 minutes before the procedure.

Intravenous administration:
Endoscopic or Cardiovascular Procedures
In healthy adults the initial dose is approximately 2.5 mg. In cases of severe illness and in elderly patients, the initial dose must be reduced to 1 to 1.5 mg.

Induction of Anesthesia
The dose is 10-15 mg I. V.

Intramuscular administration:
Adult: 0.07-0.1 mg/kg bodyweight i. m. Usual dose is about 5 mg.
Children: 0.15-0.20 mg/kg.
Elderly and debilitated patients: 0.025-0.05 mg/kg

Rectal administration in children:
For preoperative sedation, rectal administration of the ampoule solution (0.35-0.45 mg/kg) 20-30 min before induction of general anesthesia.
Side Effects
At the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. Following parenteral (IV or IM) administration of Midazolam, fluctuations in vital signs have been noted including respiratory depression, apnoea, variations in blood pressure and pulse rate.
Precautions
Midazolam IV should be administered very slowly.
Contraindications
Midazolam must not be given to patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, sleep apnea syndrome and with known hypersensitivity to benzodiazepines or to any component of the product.
Use in Pregnancy & Lactation
Midazolam should be avoided during pregnancy unless there is no safer alternative. Since Midazolam passes into breast milk, it should not be administered to breast-feeding mothers.
Overdose
Extreme overdosage may lead to coma, areflexia, cardiorespiratory depression and apnea. The effects of overdosage can be controlled with benzodiazepine antagonist flumazenil.
Commercial Packaging
Hypnofast 15 mg/3 ml Injection: Each box contains 1 ampoule of 3 ml.
Hypnofast 5 mg/1 ml Injection: Each box contains 1 ampoule of 1 ml.
Hypnofast 5 mg/5 ml Injection: Each box contains 1 ampoule of 5 ml.
Products from the same therapeutic group
Anesthetic / Critical Care
I.V Induction Agents
Ketaride
Ketamine Hydrochloride USP
Neuromuscular Blocking Agents
Nor Q
Vecuronium bromide BP 10 mg injection
Rocuron
Rocuronium Bromide INN 50 mg injection.
Regional Anesthetic
Spino
Bupivacaine Hydrochloride USP 0.5% Dextrose USP 8%
Sedative Hypnotic
Hypnofast
Midazolam
Ufol
Propofol Injection